CAPITAL STOCK AND ADDITIONAL PAID-IN CAPITAL

12 Months Ended

Jul. 31, 2025

Disclosure Capital Stock And Additional Paid In Capital [Abstract]

CAPITAL STOCK AND ADDITIONAL PAID-IN-CAPITAL [Text Block]

13. CAPITAL STOCK AND ADDITIONAL PAID-IN CAPITAL

Private Placements

On May 8, 2025, the Company completed a non-brokered private placement of $3,000,000 through the issuance of 36,585,361 units at a price of US$0.082 per unit, with each unit comprising one share of common stock and one-half of one share purchase. Each whole warrant entitles the holder to acquire one share of common stock at an exercise price of US$0.15 for a period of three years from the date of issuance. Certain directors and officers of Rise, directly, through entities controlled by them, or through entities for which they exercise control or direction over investment decisions, purchased an aggregate of 9,904,196 units for gross proceeds of $812,144. The Company paid finder's fees of $3,000 and issued a total of 36,585 finder's warrants, with each finder's warrant entitling the holder to acquire one share of common stock at a price of US$0.15 until May 8, 2028. The Company paid legal fees and other share issuance costs of $37,124 in connection with this financing.

On April 29, 2024, the Company completed a non-brokered private placement over two tranches for gross proceeds totaling $954,253 through the issuance of 10,044,765 units in total at a price of $0.095 per unit with each unit consisting of one share of common stock and one-half of one share purchase warrant. Each whole warrant entitles the holder to acquire one additional share of common stock at an exercise price of $0.158 for a period of three years from the date of issuance. Certain directors of the Company purchased an aggregate of 5,669,478 units of the private placement for gross proceeds of $538,600. The Company paid fees of $1,995 and issued 21,000 finder's warrants where each finder's warrant entitles the holder to acquire one share at a price of $0.158 for a period of two years. The Company paid legal fees of $4,515 in connection with this financing.

On December 7, 2023, the Company completed a non-brokered private placement over two tranches for gross proceeds totaling $967,957 through the issuance of 5,377,541 units in total at a price of $0.18 per unit with each unit consisting of one share of common stock and one-half of one share purchase warrant. Each whole warrant entitles the holder to acquire one additional share of common stock at an exercise price of $0.26 for a period of two years from the date of issuance. Certain directors of the Company purchased an aggregate of 2,532,220 units of the private placement for gross proceeds of $455,800. The Company paid fees of $6,480 and issued 36,000 finder's warrants where each finder's warrant entitles the holder to acquire one share at a price of $0.26 until November 7, 2025. The Company paid legal fees of $10,624 in connection with this financing.

Stock Options

On May 22, 2025, the Company granted a total of 3,320,000 stock options to directors, officers, and consultants of the Company. The stock options are exercisable at a price of US$0.10 (CAD$0.14) per share until May 22, 2030. The Company recognized a share-based compensation expense of $366,870 in connection with this grant.

On March 25, 2025 the Company granted a total of 1,142,410 stock options to directors and officers of the Company. The stock options have a fair value of $81,455 and are exercisable at a price of US$0.10 (CAD$0.14) per share until March 25, 2030. 533,103 stock options were vested immediately, and 609,307 stock options originally vested over six calendar quarters but were accelerated to fully vest on May 22, 2025. The Company recognized a share-based compensation expense of $81,455 in connection with this grant.

On October 21, 2024, the Company granted a total of 1,006,750 stock options with a fair value of $106,859 to a consultant of the Company. The stock options are exercisable at a price of $0.11 (C$0.16) per share until October 21, 2029.

On September 20, 2024, the Company granted 1,006,750 stock options to an officer of the Company. The stock options are exercisable at a price of US$0.10 (C$0.14) per share for a period of five years from the date of grant, subject to vesting, 25% vesting on the date of grant and 12% vesting every 3 months thereafter. On May 22, 2025 all unvested options were accelerated to fully vest. The Company recorded share-based compensation of $116,240 in connection with this grant.

On May 1, 2024, the Company granted a total of 1,004,479 stock options with a fair value of $140,220 to directors of the Company. The stock options are exercisable at a price of $0.17 (C$0.25) per share for a period of five years from the date of grant, subject to vesting, 25% vesting on the date of grant and 12% vesting every 3 months thereafter.  On May 22, 2025 all unvested options were accelerated to fully vest. As at July 31, 2025, the Company recorded share-based compensation of $140,220 of which $25,698 was recognized during the year ended July 31, 2025.

On December 12, 2023, the Company granted a total of 707,752 stock options with a fair value of $140,624 to directors of the Company. The stock options are exercisable at a price of $0.25 (C$0.36) per share until December 12, 2028.

On September 22, 2023, the Company granted a total of 397,780 stock options with a fair value of $90,361 to officers and directors of the Company. The stock options are exercisable at a price of $0.26 (C$0.38) per share until September 22, 2028.

The following incentive stock options were outstanding and exercisable as at July 31, 2025:

Number of Options outstanding	Weighted Average Exercise Price ($)	Expiry Date
200,000	0.65	February 7, 2027
260,000	0.53	February 21, 2028
217,780	0.26	September 22, 2028
612,202	0.25	December 12, 2028
974,479	0.17	May 1, 2029
1,006,750	0.10	September 20, 2029
1,006,750	0.11	October 21, 2029
1,142,410	0.10	March 25, 2030
3,320,000	0.10	May 22, 2030
8,740,371	0.15

As at July 31, 2025, the aggregate intrinsic value of the Company's stock options is $443,246  (2024 - $Nil). As at July 31, 2025, the Company has 8,740,371 options issued and outstanding where 8,740,371 options are exercisable as at July 31, 2025 with a weighted average exercise price of $0.15.

Stock option transactions are summarized as follows:

	Number of Options			Weighted Average Exercise Price ($)
Balance outstanding and exercisable, July 31, 2023	3,638,500			0.71
Options granted	2,110,011			0.21
Options expired	(170,000	)		0.76
Balance outstanding, July 31, 2024	5,578,511			0.52
Options granted	6,475,910			0.10
Options expired and cancelled	(3,314,050	)		0.68
Balance outstanding and exercisable, July 31, 2025	8,740,371		$	0.15

The following weighted average assumptions were used for the Black-Scholes pricing model valuation of stock options issued during the years ended July 31. 2025 and 2024:

	May 22, 2025	March 25, 2025	October 21, 2024
Risk-free interest rate	2.96%	2.72%	2.98%
Expected life of stock options	5 years	5 years	5 years
Expected annualized volatility	149.96%	145.38%	135.38%
Dividend	Nil	Nil	Nil
Forfeiture rate	0%	0%	0%

	September 20, 2024	May 1, 2024	December 12, 2023
Risk-free interest rate	2.73%	3.81%	3.53%
Expected life of stock options	5 years	5 years	5 years
Expected annualized volatility	132.92%	133.33%	131.16%
Dividend	Nil	Nil	Nil
Forfeiture rate	0%	0%	0%

Share-Based Payments

The Company has a stock option plan under which it is authorized to grant options to executive officers and directors, employees and consultants enabling them to acquire up to 10% of the issued and outstanding common stock of the Company. Under the plan the exercise price of each option equals the market price of the Company's stock, less any applicable discount, as calculated on the date of grant. The options can be granted for a maximum term of 5 years with vesting determined by the board of directors.

Warrants

The following warrants were outstanding as at July 31, 2025:

Number of Warrants	Exercise Price ($)	Expiry Date
1,623,214	0.26	November 7, 2025
36,000	0.27	November 7, 2025
1,065,555	0.26	December 7, 2025
1,000,000	0.16	February 5, 2028
9,000	0.16	April 9, 2026
2,873,170	0.16	April 9, 2027
12,000	0.16	April 29, 2026
2,149,212	0.16	April 29, 2027
1,700,000	0.12	September 12, 2028
2,882,514	0.17	October 10, 2028
18,329,266	0.15	May 8, 2028
31,679,931	0.16

Warrant transactions are summarized as follows:

	Number of Warrants			Weighted Average Exercise Price ($)
Balance outstanding and exercisable, July 31, 2023	16,661,247			0.69
Warrants granted	8,768,151			0.19
Warrants expired	(8,717,823	)		0.70
Balance outstanding, July 31, 2024	16,711,575			0.41
Warrants granted	22,911,780			0.15
Warrants expired	(7,943,424	)		0.66
Balance outstanding, July 31, 2025	31,679,931		$	0.16